CohBar, Inc.

About CohBar, Inc.

Targeting Age-Related Diseases with Underlying Metabolic Dysfunction

CohBar, Inc. is a leader in the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs with the potential to treat a wide range of diseases associated with aging and metabolic dysfunction including non-alcoholic steatohepatitis (NASH), obesity, Type 2 diabetes (T2D), cancer, cardiovascular disease and CNS disorders.

placeholder

A Mission to Increase Healthy Lifespan with MBTs

Our mission is to increase healthy lifespan by treating diseases of aging with underlying metabolic dysfunction and comorbidities. CohBar's MBTs represent an emerging class of drugs for the treatment of age-related diseases. They originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. The founder's discoveries resulted from more than 15 years of research supported by more than $30 million in grants to their academic institutions.

placeholder

Watch the CohBar Vision video

Targeting Enormous Medical Needs

Collectively, age-related diseases are the primary cause of the global epidemic of non-communicable diseases, which is already responsible for 70% of the global death rate and 80% of US Medicare costs, and which is projected to cost the global economy over $30T by 2030.

Sources: World Health Organization, CMS

Market Opportunities Within Our Targeted Diseases

Nash

Up to
29M

U.S. Patients

Greenfield Market Size
Characteristics
  • No approved therapeutics
  • Addressable market could exceed $40 billion
  • Diagnosis and treatment rapidly evolving
  • Combination therapy could optimize patient outcomes
Pharma Perspective
  • Justifies substantial investment
  • Supports multiple block-buster drugs
  • Looking to acquire and develop multiple assets
Our Advantage
  • Clear path forward with preclinical STAM data
  • Novel Mechanism of action – regulation of fat cells (adipocytes)

Obesity

80M

U.S. Patients

$4B Market Size
Characteristics
  • No safe and effective therapeutics
  • Inexpensive generics prescribed
  • Safety concerns
  • Evolving reimbursement
Pharma Perspective
  • Need safer and more efficacious drugs
  • Stronger link between obesity and NASH, T2D, cancer, cardiovascular disease
  • Treating obesity is complementary to the treatment of NASH
Our Advantage
  • Preclinical data demonstrate advantages over leading liraglutide-based obesity drug
  • Normalization of body weight in obese animals in DIO studies

Type 2 diabetes

22M

U.S. Patients

$40B Market Size
Characteristics
  • Proven clinical and regulatory pathways matched with an established market (generics and branded products)
  • Combination therapy as disease progresses
Pharma Perspective
  • Combination therapies can extend patent protection for their own blockbuster drugs
Our Advantage
  • Preclinical data demonstrates utility in combination with existing T2D therapies

(Source: Company data and other sources including CDC, NIH, WHO, World Journal of Gastroenterology, American Diabetes Association, Diabetes Management, Journal of Clinical Endocrinology and Metabolism, American Society for Metabolic and Bariatric Surgery)

Exploring the Mitochondrial Genome

We consider ourselves a first-mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides.

Our Technology

We have developed a proprietary MBT technology platform which uses cell-based assays and animal models of disease to rapidly identify mitochondrial peptides with promising biological activity.

Together these novel peptides represent a wealth of opportunities for developing MBTs with potential utility spanning the full spectrum of age-related diseases. 

View Our Technology

Pipeline - Lead Program

We have developed novel improved analogs of the MOTS-c peptide which have demonstrated significant therapeutic potential in preclinical models of obesity and nonalcoholic steatohepatitis (NASH). The Company has selected and advanced CB4211 as its lead MBT drug candidate with plans to initiate clinical trials in mid-2018.

View Our Pipeline

Pipeline - New MDP Analogs

We have an expanding group of MDP analogs that are currently emerging from the discovery process and entering the preclinical optimization stage. These include new MDPs which have demonstrated promising activity in areas like Type 2 diabetes, Alzheimer’s and cancer.

View Our Pipeline

Business Strategy

Our strategic objective is to secure, maintain and exploit a leading scientific, commercial and intellectual property position in the arena of mitochondria based therapeutics, with best-in-class treatments for diseases associated with aging and metabolic dysfunction. The key elements of our strategy include:

Advancing our lead program

through clinical trials.

Utilizing our proprietary technology platform

to continue assessing and optimizing new analogs of biologically active MDPs and advancing those MBT candidates with the greatest therapeutic and commercial potential.

Optimizing the development of our intellectual property portfolio

to capture all novel therapeutically relevant peptides encoded within the mitochondrial genome.

Developing strategic partnerships

with leading pharmaceutical companies and other organizations to advance our research programs and future development and commercialization efforts.

Minimizing operating costs and related funding requirements

for our research and development activities through careful program management and cost-efficient relationships with academic partners, consultants and contract research organizations (CROs).

Increasing awareness and recognition

of our team, assets, capabilities and opportunities within the investment and scientific communities.

Raising adequate capital

to fund our operations, research and clinical development programs.

CohBar Team - Experienced Scientists and Biotech Executives

Our leadership team is comprised of experienced scientists and biotech executives who manage and guide the Company's research and development, financing, partnering and strategic plans.

Management Team

Our Founders - World-recognized Scientific and Medical Experts

Collectively, our founders, internationally recognized leaders in their fields, have over a century's worth of background and expertise in genetics, metabolism and aging, clinical practice, research, academia, and drug development environments.

Nir Barzilai, M.D.

Dr. Barzilai is a Professor of Genetics and Director of the Institute for Aging at the Albert Einstein College of Medicine. He has been recognized for his groundbreaking work in the fields of genetics and aging, including awards and grants from the NIH, Nathan Shock and Ellison Foundations.

Pinchas Cohen, M.D.

Dr. Cohen is the Dean of the Davis School of Gerontology at the University of Southern California. Dr. Cohen has received numerous awards and grants for his work in the field of mitochondrial peptides including the EUREKA-Award and the NIH-Director-Transformative RO1 Grant.

David Sinclair, Ph.D.

Dr. Sinclair is a Professor of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for the Biological Mechanisms of Aging. Dr. Sinclair is also founder of Sirtris Pharmaceuticals, OvaScience, Genocea and ArcBio.

John Amatruda, M.D.

Dr. Amatruda has more than 35 years of experience in the pharmaceutical industry and in academia at Merck, Bayer, Rochester, Columbia and Yale Universities Schools of Medicines. He is the former SVP and Franchise Head for Diabetes and Obesity at Merck Research Labs and led the development of Merck's Januvia, a $6B/year diabetes drug.